
Accuray (NASDAQ:ARAY) specializes in the development, manufacturing, and sale of radiotherapy systems for alternative cancer treatments. The company is a pioneer in precise, innovative radiation therapy solutions, focusing on delivering life-extending treatment options to patients battling cancer. Accuray's portfolio includes the CyberKnife and TomoTherapy platforms, which are designed to deliver precise, high-dose radiation therapy with minimal damage to surrounding healthy tissue. With a global footprint, Accuray aims to expand access to its cutting-edge treatments, ensuring healthcare providers can offer advanced care to patients worldwide. The company continuously seeks to enhance its technologies and expand its reach, aiming to improve outcomes and quality of life for cancer patients.